This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Q3: Divine Skin Announces Record Quarterly Net Revenue Of $1.52 Million And Third Quarterly Net Income

MIAMI BEACH, Fla., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Today biotech pioneer Divine Skin Inc. (OTC Bulletin Board: DSKX), which went public less than a year ago, announced its third consecutive quarterly net income.

  • Q3 net revenue grew to $1.52 million — up 17 percent from last quarter and up 59 percent from the same quarter of 2009.
  • For the first nine months of 2010, net revenue increased to $3.82 million — up $1.17 million or 44 percent from the $2.65 million of the first nine months of 2009.
  • Q3 profit increased to $85,656 — up $218,669 or 164 percent from the loss of $133,013 in the same quarter of 2009.
  • For the first nine months of 2010, net income increased to $345,268 — up $422,896 or 544 percent from the $77,628 loss of the first nine months of 2009.

CEO Daniel Khesin attributed much of the growth to expanding demand for the company's consumer products. "We continue to face difficulties meeting demand from our customers, which places a strain on our supply chain and operations. Resolving these challenges is now our top priority and will lead to significant increases in revenue once we are successful. There was a lot of frustration in Q3 from our customers, who were receiving orders late due to product shortages."

Divine Skin defied the recent economic slowdown, growing quickly and without investment capital until 2009, when the developer of dermatological treatments conducted a private placement. The company began trading publicly on May 20, 2010.

Divine Skin's strategy has been to formulate effective new products by combining active ingredients already approved in existing monographs at the US Food and Drug Administration. The company thus avoids lengthy approval processes while achieving maximum efficacy and delivering new high-performance products quickly.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs